News

04/17/2018

Obsidian Therapeutics Presents Preclinical Data from Regulated Cytokine Programs that Enable CAR-T Therapies with Controllable Functions

MORE >

03/19/2018

Obsidian Therapeutics to Present at Upcoming Investor Conferences

MORE >

03/15/2018

Obsidian to Present Data on its Destabilizing Domain Technology and Product Programs at the Upcoming 2018 American Association for Cancer Research (AACR) Annual Meeting

MORE >

02/13/2018

Obsidian Therapeutics to Present Data Demonstrating Regulation of Protein Activity with its Next-Generation CAR-T Platform at Keystone Symposium on Emerging Cellular Therapies

MORE >

12/06/2017

Obsidian Therapeutics Announces $49.5 Million Series A Financing to Develop Controllable Cell and Gene Therapy Products

MORE >